Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So now we need a ticker symbol change to generate more volume and increase the price???? Yesterday we needed a conference call to do so. Before that we needed a Super 8K to do so. Before that we needed an 8K to let us know the merger was official to do so. Etc, etc, etc....nothing yet has been able to significantly raise the pps.
Or at least 5 or 6 calls today :)
Redman should probably have another conference call tomorrow
The trucks carrying the bulls to the rodeo must have broken down on the way to the rodeo...they never showed up to the rodeo so there was no rodeo today :)
Oh ya :) Will see .11 sooner than we will see .20
Fizzle, fizzle
Been "thin to .20" for the past month....old news.
Nonsense???? It's all in black and white in the 8K released today!!!! The numbers are not going to change between tonight and tomorrow.
Forgot to mention....they keep deferring compensation to somebody. It was $1,268,013 at the end of the 2016 and $1,032,623 at the end of 2015, and still rising....sooner or later that is going to be paid.
Probably by the end of the year the $2 million will be gone...then what??? $2 million were notes and AEPP (soon to be Oncolix) is required to make monthly amortization payments of 1/7th of the principal amount of the notes, commencing on the 9-month anniversary of issuance.....where will money to make payments come from????
Probably no cash now....they received proceeds (ie: cash) from the sale of convertible notes and warrants in the amount of $1,026,298 during January-March. They burned $694,867 in 3 months (Jan-Mar). Cash and cash equivalents at beginning of January were $15,264. They had $710,131 in cash at the end of March. If they burned thru another $600,000-$700,000 during April-June, then they are close to having NO CASH NOW.
June QUARTERLY will be interesting to see.
Only the beginning...more debt to come per page 11-12....
Plan of Operations for the Next Twelve Months
Our initial commercial focus is the development of Prolanta™ for the treatment of ovarian cancer. We have commenced a Phase 1 clinical trial after receiving clearance from the FDA. We completed the first dosing group of 3 subjects in the Phase I clinical trial, with no evidence of serious adverse events or dose-limiting toxicities. In order to proceed with the next doing group, we must have a contract manufacturer make a supply of new Prolanta™. We are working with contract manufacturers at this time to determine the cost and timing of new drug supplies.
This Phase I trial is an open-label safety and pharmacokinetic study in up to 18 women with recurrent or persistent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. The primary objectives of this study will be to evaluate the safety and tolerability, to determine the pharmacokinetic profile, and to determine the optimal dose of Prolanta™. We will also evaluate the effect of Prolanta™ on the ovarian cancer during the course of the study, including the effect on tumor size, blood chemistry, and tumor biochemistry.
Because of the unmet medical need in ovarian cancer, we will seek accelerated approval as soon as our studies demonstrate safety and substantial efficacy. This could be as early as the completion of two Phase II studies, but that is dependent on our clinical trial results as well as the then-current position of the FDA.
In connection with our IND filing, we conducted toxicity and pharmacokinetic studies of Prolanta™ in cynomolgus monkeys and rabbits at doses that exceeded our Phase I dose levels (adjusted for body weight of each species). These studies indicated that Prolanta™ was well tolerated, and there were no significant adverse events. The monkeys developed anti-drug antibodies, but these antibodies did not appear to have any effect on safety or the circulating life of Prolanta™ in the blood stream. It is common for biological-based drugs to result in antibody development by the subject, and the development of antibodies may have no clinical effect. Our Phase I study will also evaluate anti-Prolanta™ antibody levels in humans.
During the Phase I study, we intend to plan follow-on studies that will be conducted if the Phase I is successful. At this time, our development plan includes two Phase II studies. Because of the substantial scientific data that indicates Prolanta™ may be synergistic with current therapies, we intend to design these studies to use Prolanta™ in combination with platinum-based and taxane therapy. In the first Phase II study, one group of patients would receive Prolanta at the same time as other therapy, and the results will be compared to a second group receiving other therapy alone. The timing of this study will be dependent on the Phase I results and available resources.
We are currently evaluating improvements in our manufacturing process to increase the supply of available drug. This process may involve a change in manufacturing.
We will need additional capital to fund our development activities.
We may also in-license or acquire additional drug candidates, preferably in oncology, to expand our pipeline.
Yes, they are doing a CC for the courtesy of those, such as yourself, that have probably not read or can decipher the 8K.
Yes, hope they provide some trial data as well and not just read numbers to us like we are in grade school.
Did you not read the 8K?
Don't expect much from the CC tomorrow....
AEPP will hold a conference call on Thursday, August 10, 2017 at 8:30 am ET to review terms of the merger and debt financing.
They are only going to let us know what we already know.
On second thought, this is my favorite post from today....a bidding war broke out today??? Quickest war I ever saw. Don't stock prices rise when there are bidding wars?
Nah, this was the post of the day...suggesting an awareness program to help get more buyers...hilarious!
Hope you are right but my finger is on the sell trigger
This is old news.
Who is "they"?
Just 338 trading days to go (1/.00295) :)
Yes, I do expect some juicy news Thursday and yes my finger is on the trigger....two different things, one based on the other and nothing wrong with that.
A gain of only .003??? This was supposed to be a glorious day and the day everyone has been waiting for. The merge!!!! So many posts in the past with predictions of .25, .50. 1.00 per share when the merge occurs and “this is flying under the radar”....all a bunch of hot air and hogwash. Had to laugh when I saw a post today from someone who claimed that we need “strong buyers”.…haha, you kidding me, if “strong buyers” did not show up today, they aren’t showing up anytime soon. I’m not ready to sell yet, but my finger is on the trigger.
Expect some juicy news on the progress of Prolanta during Thursday's call!!!
Yep, agree and hope $4-5 is only 3-4 months down the road.
Also, you do realize that as common stockholders we have all been moved far down in the AEPP/Oncolix food chain?
The pps will be dictated by the Prolanta trials...nothing else matters as in the words of Metallica.
That's great that they got $$$$ to pay for clinical trials now, but the pps is going nowhere for quite awhile.
So much for being debt-free........
As part of the transaction, AEPP issued $4,190,464 aggregate principal amount of 10%, senior secured notes due November 2018. The $2,352,942 aggregate principal amount of such notes were issued at discount for $2 million in cash proceeds. Furthermore, $1,837,522 of such notes were issued in exchange for existing Oncolix debt obligations in the amount of $1,561,894. The notes are initially convertible at a fixed price into 55,932,836 shares of AEPP common stock subject to future adjustment. AEPP is required to make monthly amortization payments of 1/7 [th] of the principal amount of the notes, commencing on the 9-month anniversary of issuance. The notes are secured by all the assets of AEPP and Oncolix and guaranteed by Oncolix. Additionally, five-year warrants to purchase 55,932,836 shares of AEPP common stock at an exercise price of $0.09 per share were issued in connection with the debt financing. In connection with the issuance of these notes and warrants, the Company granted registration rights to register the resale of the shares underlying both the notes and warrants.
The "fake paper merger" is now dead and the real merger is on!!!
Awesome!!!!!
Tears of joy roll down my cheeks every time I read this:
Regulatory Plans. Oncolix has an FDA-cleared IND to commence the Phase I study of Prolanta to treat ovarian cancer. Furthermore, Prolanta was granted orphan designation by the FDA for the treatment of ovarian cancer. Because of the unmet medical needs in ovarian cancer, Oncolix will seek accelerated approval after the Phase IIb study, or will roll the Phase IIb results into a Phase III study. Studies in other indications (breast, endometrial cancer and others) are deferred until later in the clinical development process unless the Company receives additional funding to commence these trials or the Company enters into a strategic partnership with a large pharmaceutical company.
Targeted therapies are expensive treatments. In the US, Herceptin sells for $64,000 per year (Source: Genentech) and the annual cost of Avastin is $55,000 to more than $80,000 per year, depending on income. If Prolanta could achieve a 5% market share of the US and European prevalence of ovarian cancer, at least $35,000 per patient per year, revenues would surpass $1 billion per year.
Source:
https://www.oncolixbio.com/ovarian-cancer-and-prolanta.html
Mr. Michael T. Redman, B.A (Biology), M.B.A., has been Chairman, President and Principal Financial Officer of Advanced Environmental Petroleum Producers, Inc. since January 19, 2017 and has been Chief Executive Officer since April 6, 2017. Mr. Redman has been Chief Executive Officer of Oncolix, Inc. since November 2006. Prior to forming Oncolix, Mr. Redman co-founded Opexa Pharmaceuticals, Inc. in February 2001 and served as its Chief Executive Officer & President. He served as the Chief Executive Officer of Bone Medical Ltd. from February 28, 2005 to November 7, 2005. Previously, he served as President, Chief Executive Officer and a Director at Opexa Pharmaceuticals. His career combines sales, marketing, business and commercial development experience gained over 25 years in the pharmaceutical and biotechnology industry. Mr. Redman also served as Vice-President of Corporate Development at Aronex Pharmaceuticals, Inc. and as Vice-President of Business Development at Zonagen, Inc. He was formerly Vice-President of Marketing & Sales at Biovail. He has a distinguished track record in the area of licensing, sales and marketing and has consummated licensing deals with many large pharmaceutical companies, both domestic and international. He was employed at Repros Therapeutics Inc. He has been a Director of Advanced Environmental Petroleum Producers, Inc. since April 6, 2017. He serves as Director of Opexa Pharmaceuticals, Inc. and Oncolix, Inc. He also serves as a director of the Licensing Executive's Society. He served as Director of Bone Medical Ltd. from February 28, 2005 to November 7, 2005. Mr. Redman has work experience in large pharmaceutical companies, including Monsanto and American Home Products. Mr. Redman received his B.A. in Biology from the University of Missouri and a Masters in Business Administration from the University of Phoenix.
Source:
https://www.bloomberg.com/research/stocks/private/person.asp?personId=200766&privcapId=317012132
Dozens maybe hundreds of biotechs have never and will never make any money.....it's all based on perception and successful clinical trials. If you need an example to prove my point take a look:
http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=MESO.O
Mesoblast has never and never will have income.
Friday August 4th...Last day to buy at a discount!!!!
Silence is going to be golden $$$$$$$$$$$$$$
Minor detail...will buy when they are public then
No worries...I'll be one of the first to buy most or all of those 950,000,000 shares
Awesome post!!! Thanks BlackDoggie!